# Study to Assess a Booster Dose of GBS-NN/NN2 Vaccine

> **NCT05005247** · PHASE1 · COMPLETED · sponsor: **Minervax ApS** · enrollment: 27 (actual)

## Conditions studied

- Group B Streptococcus Infection

## Interventions

- **BIOLOGICAL:** GBS-NN/NN2

## Key facts

- **NCT ID:** NCT05005247
- **Lead sponsor:** Minervax ApS
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-17
- **Primary completion:** 2022-08-05
- **Final completion:** 2022-08-05
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2024-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05005247

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05005247, "Study to Assess a Booster Dose of GBS-NN/NN2 Vaccine". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05005247. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*